Saturday 17 October 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.48
0.45
−2.38%
Follow NVCT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
2.38 | 2.09 | 2.75 | 3.30 | 2.41 | 0.00 | — |
Net Debt/EBITDA |
1.15 | 0.93 | 0.84 | 1.04 | 0.45 | 0.00 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.55 | 0.64 | 0.72 | 0.71 | 0.74 | 0.00 | — |
| (205.30%) | (173.41%) | (168.51%) | (1,188.73%) | 233.98% | 0.18% | — | |
| (114.76%) | (100.55%) | (112.45%) | (141.05%) | (387.26%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(156.80%) | (195.61%) | (182.44%) | (134.22%) | (377.56%) | 100.00% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.73) | (0.72) | (1.03) | (1.07) | (2.23) | 0.00 | — |
Cash per Share |
1.45 | 1.08 | 1.23 | 1.58 | 1.35 | 0.00 | — |
Shareholders Equity per Share |
0.84 | 0.57 | 0.78 | 1.12 | (2.58) | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.84 | 0.57 | 0.78 | 1.12 | (2.58) | 0.00 | — |
Free Cash Flow |
(16.01) | (12.25) | (15.95) | (13.56) | (9.50) | — | — |
Working Capital |
18.41 | 9.71 | 12.20 | 14.22 | 3.41 | (0.01) | — |
Net Current Asset Value |
18.41 | 9.71 | 12.20 | 14.22 | (11.83) | (0.01) | — |
| Other line items | |||||||
Quick Ratio |
2.38 | 2.08 | 2.74 | 3.23 | 2.37 | 0.00 | — |
Cash ROIC |
(31.99%) | (43.36%) | (50.93%) | (39.63%) | 180.48% | 0.00% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.73) | (0.72) | (1.03) | (1.07) | (2.23) | 0.00 | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
4.39 | 2.63 | 2.84 | 1.98 | 0.53 | — | — |
Average Assets |
25.16 | 18.90 | 19.80 | 13.53 | 3.33 | 0.00 | — |
Average Common Equity |
14.06 | 10.96 | 13.21 | 1.61 | (5.51) | (5.51) | — |
Columns are period end dates